The stock of TG Therapeutics Inc (NASDAQ:TGTX) is a huge mover today! About 284,518 shares traded hands. TG Therapeutics Inc (NASDAQ:TGTX) has declined 28.79% since March 15, 2016 and is downtrending. It has underperformed by 34.28% the S&P500.
The move comes after 8 months positive chart setup for the $316.85 million company. It was reported on Oct, 18 by Barchart.com. We have $8.55 PT which if reached, will make NASDAQ:TGTX worth $107.73M more.
Analysts await TG Therapeutics Inc (NASDAQ:TGTX) to report earnings on November, 14. They expect $-0.32 earnings per share, down 14.29% or $0.04 from last year’s $-0.28 per share. After $-0.33 actual earnings per share reported by TG Therapeutics Inc for the previous quarter, Wall Street now forecasts -3.03% EPS growth.
TG Therapeutics Inc (NASDAQ:TGTX) Ratings Coverage
Out of 6 analysts covering TG Therapeutics (NASDAQ:TGTX), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. TG Therapeutics has been the topic of 7 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Brean Capital reinitiated TG Therapeutics Inc (NASDAQ:TGTX) on Thursday, October 6 with “Buy” rating. H.C. Wainwright reinitiated TG Therapeutics Inc (NASDAQ:TGTX) on Wednesday, August 12 with “Buy” rating. The firm has “Strong Buy” rating given on Wednesday, September 9 by Raymond James. The firm has “Hold” rating given on Wednesday, August 12 by Zacks. The stock of TG Therapeutics Inc (NASDAQ:TGTX) has “Buy” rating given on Friday, May 27 by SunTrust. As per Friday, May 27, the company rating was initiated by Suntrust Robinson. The stock has “Outperform” rating given by FBR Capital on Tuesday, December 1.
According to Zacks Investment Research, “TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.”
Insitutional Activity: The institutional sentiment increased to 1.54 in 2016 Q2. Its up 0.09, from 1.45 in 2016Q1. The ratio is positive, as 10 funds sold all TG Therapeutics Inc shares owned while 18 reduced positions. 14 funds bought stakes while 29 increased positions. They now own 29.49 million shares or 0.54% more from 29.33 million shares in 2016Q1.
Pictet Asset Mgmt Ltd has 1.22 million shares for 0.04% of their US portfolio. The Illinois-based Northern Tru Corp has invested 0% in TG Therapeutics Inc (NASDAQ:TGTX). Moreover, Ladenburg Thalmann Services has 0% invested in TG Therapeutics Inc (NASDAQ:TGTX) for 2,539 shares. Teacher Retirement System Of Texas accumulated 0% or 5,939 shares. State Street reported 624,307 shares or 0% of all its holdings. Rhumbline Advisers reported 37,547 shares or 0% of all its holdings. Jpmorgan Chase has 0% invested in the company for 157 shares. Citadel Advsr Lc accumulated 0% or 44,001 shares. Eventide Asset Mngmt Lc accumulated 0.2% or 537,600 shares. Vanguard Group Inc holds 1.48 million shares or 0% of its portfolio. One Trading Lp has 0% invested in the company for 1,154 shares. California Pub Employees Retirement Systems last reported 124,800 shares in the company. Geode Capital Mngmt Ltd Com reported 277,277 shares or 0% of all its holdings. Numeric Invsts has invested 0% of its portfolio in TG Therapeutics Inc (NASDAQ:TGTX). Bank Of New York Mellon Corporation last reported 0% of its portfolio in the stock.
Insider Transactions: Since July 5, 2016, the stock had 0 insider buys, and 1 sale for $302,052 net activity. Power Sean A had sold 50,426 shares worth $302,052.
Another recent and important TG Therapeutics Inc (NASDAQ:TGTX) news was published by Fool.com which published an article titled: “Why TG Therapeutics, Inc. Stock Is Dropping Today” on October 13, 2016.
TGTX Company Profile
TG Therapeutics, Inc. (TG), incorporated on May 18, 1993, is a biopharmaceutical firm focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Firm is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes. The Firm is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Firm also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti-PD-L1 and anti-GITR antibodies. The Firm also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and investment opportunities.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.